Black mold on the equipment. Lab papers shoved into lockers as inspectors walked in. That's what FDA inspectors say they found at a plant making ingredients for compounded GLP-1s. It's Monday, and this is GLP-1 Daily. We start with those two Chinese suppliers. Then who gets denied on a first GLP-1 prescription, and Europe's regulators backing Lilly's pill.
Kalbir Talwar, writing for Briefs:
Inspection reports describe a mess at two Chinese facilities supplying active ingredients for compounded GLP-1 drugs. At Chengdu Shengnuo, inspectors noted black mold on equipment, "gross contamination" on floors, and "significant insect activity" in the ceilings.
The reports came out through a records request. At Chengdu Shengnuo in August, inspectors say quality staff rushed lab papers into lockers while workers dumped product samples into sinks, in what the report calls a seemingly coordinated effort. Then in September, at Nanjing Chengong Pharmaceutical, the report says staff bought ingredients made by other manufacturers and stamped their own approval seal on them without checking the testing data. The FDA has added both companies to its import-alert list, so their shipments can be stopped at the border. Chengdu Shengnuo says in a Chinese regulatory filing that it's fixing the problems. Neither company answered emailed questions. And agency records list the plants' previous inspections as September 2023 and March 2025. Before anyone panics: compounders have to buy ingredients from FDA-registered manufacturers, and the FDA spot-checks those suppliers. This is that system catching two of them, not proof every compounded vial is suspect. But Brookings found a substantial share of the ingredients in compounded GLP-1s come from China, and the people relying on those vials are often the ones insurance already turned away. Michael Rogers, a former FDA associate commissioner for inspections, says the findings suggest a serious accident waiting to happen. If you're on a compounded GLP-1, it's fair to ask your prescriber and your pharmacy whether it comes from a registered 503A or 503B facility, and where the active ingredient is sourced.
Miaoqing Jia and colleagues at Weill Cornell and Johns Hopkins, in Health Affairs Scholar:
Denial was higher in Medicaid than commercial coverage (12.6% versus 5.6%) and for obesity-indicated than diabetes-indicated brands (16.8% versus 6.3%). Among individuals with a denied index claim, 34.1% obtained a paid fill within 90 days, declining from 45.9% (2018) to 24.8% (2024).
Let me put that in plain terms. Take someone's very first GLP-1 prescription. On an obesity brand, it got denied about one time in six. On a diabetes brand, about one in sixteen. Medicaid patients were denied more than twice as often as people on commercial plans. And by 2024, only about a quarter of the people who got denied had a paid fill within three months. Most never got one. It's peer-reviewed, posted Thursday, and built on national multi-payer pharmacy claims from 2018 through 2024, so it predates this year's employer pullback and the Medicare Bridge. The abstract page doesn't list a funder, and it can't tell us whether the people who never got a paid fill paid cash, switched drugs, or gave up. Overall denials peaked at nine point six percent in 2022 and fell to six point six by 2024. That sounds like progress. But over the same stretch, the share of people who got past a denial dropped by almost half. So fewer people get the no, and the people who do get it are more likely to stay stuck with it. A first denial doesn't have to be the last word. If it happens to you, ask your prescriber's office whether an appeal or a resubmitted prior authorization makes sense before you drop it.
Biotech Research, on the European Medicines Agency committee's vote:
The positive opinion covers two separate indications. For weight management, EMA's recommendation is based on two studies involving more than 4,740 adults with obesity or overweight. Participants treated with orforglipron for 72 weeks lost approximately 5 to 11 per cent of their body weight depending on dose, compared with approximately 2 to 2.5 per cent in placebo groups.
That's Foundayo, Lilly's orforglipron. The EMA's human medicines committee adopted a positive opinion on Thursday, October 15, covering obesity and type 2 diabetes in adults. It's a recommendation for now. The European Commission makes the binding decision, and Biotech Research says that usually follows within a few weeks. Those figures come from Lilly's own trials, as summarized by the regulator. What's different is the format: a small molecule, not a peptide, taken any time of day without the food and water rules of other oral GLP-1s. Anyone who's done the Wegovy pill's morning routine knows that's a big deal. Britain authorized Foundayo in August, but NICE now expects its NHS guidance on January 27, 2027. Licensed and paid for are two separate finish lines. One fix to that write-up. It says orforglipron's cardiovascular outcomes data is still pending. On Friday, October 9, we covered ACHIEVE-4 in The Lancet, where orforglipron was non-inferior to insulin glargine on major cardiovascular events in people with type 2 diabetes. Foundayo has been sold in the U.S. since April, so if a pill without fasting rules sounds like a better fit for you, bring it up with your prescriber.
If this briefing saved you some digging this week, take a moment to rate or review GLP-1 Daily in your podcast app. It's the easiest way for another patient to find us.
You'll find all three sources in the episode notes. That's Monday's GLP-1 Daily. We're back tomorrow with Tuesday's briefing, and this show is a Lantern Podcast.